Literature DB >> 23341590

Lessons learned and concepts formed from study of the pathogenesis of the two negative-strand viruses lymphocytic choriomeningitis and influenza.

Michael B A Oldstone1.   

Abstract

Viruses have unique lifestyles. To describe the pathogenesis and significance of viral infection in terms of host responses, resultant injury, and therapy, we focused on two RNA viruses: lymphocytic choriomeningitis (LCMV) and influenza (Flu). Many of the currently established concepts and consequences about viruses and immunologic tolerance, virus-induced immunosuppression, virus-induced autoimmunity, immune complex disease, and virus-lymphocyte and virus-dendritic cell interactions evolved through studies of LCMV in its natural murine host. Similarly, the mechanisms, aftermath, and treatment of persistent RNA viruses emerged, in large part, from research on LCMV. Analysis of acute influenza virus infections uncovered the prominent direct role that cytokine storm plays in the pathogenesis, morbidity, and mortality from this disease. Cytokine storm of influenza virus infection is initiated via a pulmonary endothelial cell amplification loop involving IFN-producing cells and virus-infected pulmonary epithelial cells. Importantly, the cytokine storm is chemically treatable with specific agonist therapy directed to the sphingosphine 1 phosphate receptor 1, which is located on pulmonary endothelial cells, pointing to the endothelial cells as the gatekeepers of this hyperaggressive host immune response.

Entities:  

Mesh:

Year:  2013        PMID: 23341590      PMCID: PMC3600446          DOI: 10.1073/pnas.1222025110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

Review 1.  Biology and pathogenesis of lymphocytic choriomeningitis virus infection.

Authors:  M B A Oldstone
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

Review 2.  Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin.

Authors:  M B Oldstone
Journal:  Prog Med Virol       Date:  1975

3.  The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes).

Authors:  M B Oldstone; T Aoki; F J Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

4.  Lymphocytic choriomeningitis: production of antibody by "tolerant" infected mice.

Authors:  M B Oldstone; F J Dixon
Journal:  Science       Date:  1967-12-01       Impact factor: 47.728

5.  Autologous immune responses to the major oncornavirus polypeptides in unmanipulated AKR/J mice.

Authors:  M B Oldstone; B C Del Villano; F J Dixon
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

6.  Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.

Authors:  Darwyn Kobasa; Ayato Takada; Kyoko Shinya; Masato Hatta; Peter Halfmann; Steven Theriault; Hiroshi Suzuki; Hidekazu Nishimura; Keiko Mitamura; Norio Sugaya; Taichi Usui; Takeomi Murata; Yasuko Maeda; Shinji Watanabe; M Suresh; Takashi Suzuki; Yasuo Suzuki; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  Nature       Date:  2004-10-07       Impact factor: 49.962

Review 7.  Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.

Authors:  Michael B A Oldstone; John R Teijaro; Kevin B Walsh; Hugh Rosen
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

8.  Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion.

Authors:  Noemí Sevilla; Dorian B McGavern; Chao Teng; Stefan Kunz; Michael B A Oldstone
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

9.  T-cell tolerance: exposure to virus in utero does not cause a permanent deletion of specific T cells.

Authors:  B D Jamieson; R Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells.

Authors:  N Sevilla; S Kunz; A Holz; H Lewicki; D Homann; H Yamada; K P Campbell; J C de La Torre; M B Oldstone
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

View more
  15 in total

1.  Cutting Edge: B Cell-Intrinsic T-bet Expression Is Required To Control Chronic Viral Infection.

Authors:  Burton E Barnett; Ryan P Staupe; Pamela M Odorizzi; Olesya Palko; Vesselin T Tomov; Alison E Mahan; Bronwyn Gunn; Diana Chen; Michael A Paley; Galit Alter; Steven L Reiner; Georg M Lauer; John R Teijaro; E John Wherry
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

2.  Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

Authors:  Jonathan P McNally; Scott H Millen; Vandana Chaturvedi; Nora Lakes; Catherine E Terrell; Eileen E Elfers; Kaitlin R Carroll; Simon P Hogan; Paul R Andreassen; Julie Kanter; Carl E Allen; Michael M Henry; Jay N Greenberg; Stephan Ladisch; Michelle L Hermiston; Michael Joyce; David A Hildeman; Jonathan D Katz; Michael B Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

3.  PA-X decreases the pathogenicity of highly pathogenic H5N1 influenza A virus in avian species by inhibiting virus replication and host response.

Authors:  Jiao Hu; Yiqun Mo; Xiaoquan Wang; Min Gu; Zenglei Hu; Lei Zhong; Qiwen Wu; Xiaoli Hao; Shunlin Hu; Wenbo Liu; Huimou Liu; Xiaowen Liu; Xiufan Liu
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

4.  Profile of Michael B. A. Oldstone. Interview by Nicholette Zeliadt.

Authors:  Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

5.  iTRAQ-based quantitative proteomics reveals important host factors involved in the high pathogenicity of the H5N1 avian influenza virus in mice.

Authors:  Jiao Hu; Zhao Gao; Xiaoquan Wang; Min Gu; Yanyan Liang; Xiaowen Liu; Shunlin Hu; Huimou Liu; Wenbo Liu; Sujuan Chen; Daxin Peng; Xiufan Liu
Journal:  Med Microbiol Immunol       Date:  2016-12-20       Impact factor: 3.402

6.  Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection.

Authors:  Carys S Kenway-Lynch; Arpita Das; Andrew A Lackner; Bapi Pahar
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

7.  Lack of T-cell-mediated IL-2 and TNFα production is linked to decreased CD58 expression in intestinal tissue during acute simian immunodeficiency virus infection.

Authors:  Diganta Pan; Arpita Das; Sudesh K Srivastav; Vicki Traina-Dorge; Peter J Didier; Bapi Pahar
Journal:  J Gen Virol       Date:  2018-11-29       Impact factor: 3.891

8.  Structure of the LCMV nucleoprotein provides a template for understanding arenavirus replication and immunosuppression.

Authors:  Brandyn R West; Kathryn M Hastie; Erica Ollmann Saphire
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-05-30

9.  Characterization of host proteins interacting with the lymphocytic choriomeningitis virus L protein.

Authors:  Kseniya Khamina; Alexander Lercher; Michael Caldera; Christopher Schliehe; Bojan Vilagos; Mehmet Sahin; Lindsay Kosack; Anannya Bhattacharya; Peter Májek; Alexey Stukalov; Roberto Sacco; Leo C James; Daniel D Pinschewer; Keiryn L Bennett; Jörg Menche; Andreas Bergthaler
Journal:  PLoS Pathog       Date:  2017-12-20       Impact factor: 6.823

10.  Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV.

Authors:  Kathryn M Hastie; Sébastien Igonet; Brian M Sullivan; Pierre Legrand; Michelle A Zandonatti; James E Robinson; Robert F Garry; Félix A Rey; Michael B Oldstone; Erica Ollmann Saphire
Journal:  Nat Struct Mol Biol       Date:  2016-04-25       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.